Agios Pharmaceuticals will stop developing its experimental drug Tebapivat for lower-risk myelodysplastic syndromes after a trial failed to meet efficacy thresholds [1].
The decision removes a potential treatment option for patients with this specific blood cancer, highlighting the high failure rate of targeted oncology therapies in mid-stage clinical trials.
Company officials said the move on May 29, 2026 [2]. The discontinuation follows a phase-2b trial that included 65 patients [1]. According to the company, the results did not meet the predefined efficacy threshold required to justify further development [1].
Myelodysplastic syndromes are a group of cancers where the bone marrow does not produce enough healthy blood cells. The drug candidate, Tebapivat, was specifically being tested for lower-risk cases of the disease [2].
Agios, headquartered in Cambridge, Massachusetts, released the update via a company press release [2]. The company did not provide a specific timeline for how this shift affects its broader oncology pipeline, but the failure of the phase-2b trial marks a definitive end for this specific candidate in this indication [1].
Clinical trials in the phase-2b stage are critical for determining whether a drug has enough benefit to warrant the massive investment of a phase-3 study. In this case, the benefit was deemed insufficient [1].
“Agios will stop developing its experimental drug Tebapivat”
The discontinuation of Tebapivat reflects the volatility of biotech development, where a single failed trial can eliminate years of research. For patients with lower-risk myelodysplastic syndromes, this represents a lost opportunity for a new therapeutic avenue, shifting the focus back to existing standard-of-care treatments while the industry awaits more successful targeted therapies.
